David Maheu

David Maheu has a vast work experience in the biopharmaceutical industry, specializing in viral vector development and manufacturing. David held leadership positions at various companies such as Candel Therapeutics, Bellicum Pharmaceuticals, Aruvant, Ultragenyx Pharmaceutical Inc., Sarepta Therapeutics, MilliporeSigma, and Amgen. David'sroles included overseeing process and analytical development, viral vector manufacturing, process development, and pilot plant operations. David's expertise lies in gene therapy, cell therapy, and bioprocessing, with a strong focus on AAV-based programs and CAR-T therapies.

David Maheu attended Plymouth State University from 1993 to 1997, where they obtained a B.Sc in Biology, General.